MorphosSys Therapy and Revlimid Eliminate Cancer in a Third of DLBCL Patients, Phase 2 Trial Shows
News
A combination of MorphoSys‘ MOR208 and Revlimid (lenalidomide) eliminated cancer cells in almost a third of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a Phase 2 clinical trial shows. Tumor ... Read more